Inclusion Criteria:

- Male or female patients who are 18 years of age or older with diffuse large B-cell
cell lymphoma (DLBCL) relapsed or refractory after initial therapy who:

- Are not candidates for autologous stem cell transplant.

- Have relapsed after autologous or allogeneic stem cell transplant.

- Have relapsed or refractory disease after 3 successive chemotherapy regimens.

- ECOG Performance Score 0-2

- Creatinine clearance > 60 mL/min/1.73 m2.

- Total bilirubin ≤2.0 X Institutional Upper Limit of Normal (IULN)

- AST (SGOT)/ALT (SGPT) ≤2.5 X IUNL, or ≤5X IUNL in patients with liver involvement of
DLBCL

- Absolute neutrophil count >1,000 /_L; hemoglobin >9 g/mL; platelet count > 75,000 /_L
at screening.

- Patients must be capable of understanding the purpose and risks of the study and able
to provide written consent.

- Patients must be willing and able to comply with the prescribed treatment protocol
and evaluations

Exclusion Criteria:

- Treatment with experimental (unlicensed) drug within 3 weeks of treatment.

- Previous chemotherapy, or major surgery within 21 days prior to first study
treatment, or radiation therapy within 6 weeks.

- Rapidly progressive disease or organ function threatened by disease

- Serious, uncontrolled active infections.

- Serologically positive for HIV, HBV, or HCV.

- Clinically significant cardiac, pulmonary, and/or hepatic dysfunction

- Lymphoma involving the central nervous system

- Female patients who are pregnant or breast feeding.

- Patients not capable of understanding the purpose and risks of the study and or
unable to provide written consent.

- Patients not willing and or unable to comply with the prescribed treatment protocol
and evaluations